February 03, 2025

Chemotherapy Linked to Chronic Neuropathy for 4 in Every 10 Patients: Global Analysis Results

Platinum-based drugs, taxanes, and lung cancer seem to be associated with the highest rates of persistent painful neuropathy, defined as lasting at least 3 months.

The ASCO Post

February 03, 2025

Cancer Symptoms Mistaken for Pregnancy Symptoms Could Lead to Delays in Cancer Diagnosis

Pregnant patients may be at risk of having their cancer symptoms misdiagnosed as pregnancy-related symptoms.

The ASCO Post

February 03, 2025

Salpingectomy During Other Abdominal Surgeries May Lower Ovarian Cancer Risk

Researchers have examined whether fallopian tube removal performed during other abdominal surgeries could reduce the risk of ovarian cancer incidence.

The ASCO Post

February 03, 2025

Addition of Bevacizumab to Pembrolizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

In a Singaporean phase II trial reported in The Lancet Oncology, Chong et al found that the addition of bevacizumab to pembrolizumab improved objective response rate in patients with platinum-resistan...

The ASCO Post

February 03, 2025

Thermal Ablation vs Surgical Resection of Small Resectable Colorectal Liver Metastases

In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation was noninferior to surgical resection in terms of ...

The ASCO Post

February 01, 2025

Being Part of the Solution

Because dentists are medical professionals whom patients may visit two or three times a year, opportunities can arise for a dentist to be “part of the solution” when it comes to a patient’s overall health.

Compendium

January 31, 2025

Hereditary Ovarian Cancer Risk: Unlocking New Insights

Approximately 40% of high-grade serous ovarian cancer cases have a significant hereditary component. Researchers have uncovered new heredity genes that may contribute to an increased risk of developin...

The ASCO Post

January 31, 2025

TACE and Durvalumab/Bevacizumab in Unresectable HCC

“Durvalumab plus bevacizumab plus [transarterial chemoembolization (TACE)] has the potential to set a new standard of care” in this patient population, according to researchers who conducted the EMERA...

The ASCO Post

January 31, 2025

Does Brain MRI Surveillance Benefit Asymptomatic Patients With Stage IV Breast Cancer?

Asymptomatic brain metastasis may be more common in patients with stage IV breast cancer than previously understood, according to findings from a recent phase II trial.

The ASCO Post